Date: July 24th, 2022 Your Name: Elena Neumann Manuscript Title: Predictors Associated with Mortality of Veno-Venous Extracorporeal Membrane Oxygenation Therapy

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame. Since the finitian	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees		

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

None

Please place an "X" next to the following statement to indicate your agreement:

_X_I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: 27.08.2022 Your Name: Sebastian D Sahli

Manuscript Title: Predictors Associated with Mortality of Veno-Venous Extracorporeal Membrane Oxygenation Therapy Manuscript number (if known): n/a

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
2	Grants or contracts from any entity (if not indicated in item #1 above). Royalties or licenses	Time frame: pastX_None X_None X_None	36 months
-			
4	Consulting fees	XNone	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony	XNone XNone
7	Support for attending meetings and/or travel	XNone
8	Patents planned, issued or pending	X_None
9	Participation on a Data Safety Monitoring Board or Advisory Board	X_None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone
11	Stock or stock options	XNone
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None
13	Other financial or non- financial interests	X_None

Sebastian D Sahli has no conflicts of interests to declare.

Please place an "X" next to the following statement to indicate your agreement:

__X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: 31.08.2022 Your Name: Alexander Kaserer Manuscript Title: Predictors Associated with Mortality of Veno-Venous Extracorporeal Membrane Oxygenation Therapy Manuscript number: n/a

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees		

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Bayer AG (Switzerland)	
6	Payment for expert testimony	X_None	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	X_None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone	
13	Other financial or non- financial interests	XNone	

Dr. Kaserer has received support from Bayer AG (Switzerland) for lecturing.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: 22.08.2022
Your Name: Julia Braun
Manuscript Title: Predictors Associated with Mortality of Veno-Venous Extracorporeal Membrane
Oxygenation Therapy
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initial None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
6	educational events	N	
6	Payment for expert	None	
	testimony		
7	Support for attending	None	
/	meetings and/or travel		
	5 ,		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	None	
11			
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: July 09th, 2022 Your Name: Muriel Spahn Manuscript Title: Predictors Associated with Mortality of Veno-Venous Extracorporeal Membrane Oxygenation Therapy

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees		

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

None

Please place an "X" next to the following statement to indicate your agreement:

_X_I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:	_15.08.2022	
Your Name:_	RaedAser	
Manuscript 1	Title:_ Predictors Associated with Mortality of Veno-Venous Extracorporeal Membrane Ox	kygenation
Therapy		
Manuscript r	number (if known):xx	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	
1	All support for the present manuscript (e.g., funding,	x_None	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	t 36 months
2	Grants or contracts from	xNone	
	any entity (if not indicated		۰. ۲
	in item #1 above).		
3	Royalties or licenses	x_None	
4	Consulting fees	xNone	
п			

	a An an an an an an an an Anna an		
5	Payment or honoraria for lectures, presentations, speakers bureaus,	x_None	
	manuscript writing or educational events		
6	Payment for expert	_xNone	
	testimony		а
7	Support for attending meetings and/or travel	x_None	
	incenings and/or traver		
8	Patents planned, issued or pending	xNone	
9	Participation on a Data	x_None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	x_None	
	in other board, society, committee or advocacy		· · · ·
	group, paid or unpaid	6	
11	Stock or stock options	x_None	
12	Receipt of equipment,	x None	
12	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non- financial interests	x_None	

XXX

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this

Asy Rol

Ase Rul

form.

Date: 11.08.2022 Your Name: Donat R. Spahn Manuscript Title: Predictors Associated with Mortality of Veno-Venous Extracorporeal Membrane Oxygenation Therapy Manuscript number (if known):______

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Time frame: Since the initial	planning of the work
All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
	Timo framo: past	36 months
Grants or contracts from any entity (if not indicated in item #1 above).	nnie frame: past	DRS academic department is receiving grant support from the Swiss National Science Foundation, Berne, Switzerland, the Swiss Society of Anesthesiology and Perioperative Medicine (SSAPM), Berne, Switzerland, the Swiss Foundation for Anesthesia Research, Zurich, Switzerland, Vifor SA, Villars-sur-Glâne, Switzerland and Vifor (International) AG, St. Gallen, Switzerland.
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated	Whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated

3 Royalties or licenses	None		
5 Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events DRS received honoraria / travel support for cor lecturing from: Danube University of Krems, Austria, European of Anesthesiology and Intensive Care, Brussels, Korean Society for Patient Blood Management, Korea, Korean Society of Anesthesiologists, See Network for the Advancement of Patient Blood Management, Haemostasis and Thrombosis, Pa France, Alexion Pharmaceuticals Inc., Boston, N. Astra2eneca AG, Baar, Switzerland, Bergen Inte II Sàrl, Couvet, Switzerland, Dailchi Sankyo AG, Switzerland, B. Braun Melsungen AG, Melsunge Germany, and Berne, Switzerland, Celgene Inte II Sàrl, Couvet, Switzerland, Dailchi Sankyo AG, Switzerland, Haemootics, Braintree, MA, USA, Instrumentation Laboratory (Werfen), Bedford USA, LFB Biomédicaments, Courtaboeuf Cedex, Merck Sharp & Dohme, Kenilworth, New Jersey Novo Nordis Health Care AG, Surich, Switzerland, Pierre Fabre Pharma, Alsch Switzerland, Pierre Fabre Pharma, Alsch Switzerland, Starstedt AG & Co., Sevelen, Switzerland Germany, Natiserland, Pierre Fabre Pharma, Alsch Switzerland, Starstedt AG & Co., Sevelen, Switzerland Managones, Switzerland, Uffor (International) Ltd, Reinach, Switzerland, Takeda, Glattpark, Switzerland, Gallen, Switzerland, Takeda, Glattpark, Switzerland, Al Singapore. 6 Payment for expert testimony XNone 7 Support for attending None			
5 Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events DRS received honoraria / travel support for cor lecturing from: Danube University of Krems, Austria, European of Anesthesiology and Intensive Care, Brussels, Korean Society for Patient Blood Management, Korea, Korean Society of Anesthesiologists, See Network for the Advancement of Patient Blood Management, Haemostasis and Thrombosis, Pa France, Alexion Pharmaceuticals Inc., Boston, N. Astra2eneca AG, Baar, Switzerland, Bayer AG, Z Switzerland, B. Braun Melsungen AG, Melsunge Germany, and Berne, Switzerland, Calgene Inter II Sàrl, Couvet, Switzerland, Daiichi Sankyo AG, Switzerland, Haemootics, Braintree, MA, USA, Instrumentation Laboratory (Werfen), Bedford USA, LFB Biomédicaments, Courtaboeuf Cedex, Merck Sharp & Dohme, Kenilworth, New Jersey Novo Nordis Health Care AG, Sturich, Switzerland, Reiman, Pharmacosmos A/S, Holaek, Demark, Pitzer - Zürich, Switzerland, Startedt AG & Co., Sevelen, Switzerland, Switzerland, Scattedt AG & Co., Sevelen, Switzerland Germany, Naing Startet AG & Co., Sevelen, Switzerland Mark, Pitzer - Zürich, Switzerland, Gattupark, Switzerland, Switzerland, Tekeda, Gattupark, Switzerland, Switzerland, Takeda, Glattupark, Switzerland, Alexine, Singapore. 6 Payment for expert testimony			
5 Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events DRS received honoraria / travel support for cor lecturing from: Danube University of Krems, Austria, European of Anesthesiology and Intensive Care, Brussels, Korean Society for Patient Blood Management, Korea, Korean Society of Anesthesiologists, See Network for the Advancement of Patient Blood Management, Haemostasis and Thrombosis, Pa France, Alexion Pharmaceuticals Inc., Boston, N. Astra2eneca AG, Baar, Switzerland, Bergen Inte II Sàrl, Couvet, Switzerland, Dailchi Sankyo AG, Switzerland, B. Braun Melsungen AG, Melsunge Germany, and Berne, Switzerland, Celgene Inte II Sàrl, Couvet, Switzerland, Dailchi Sankyo AG, Switzerland, Haemootics, Braintree, MA, USA, Instrumentation Laboratory (Werfen), Bedford USA, LFB Biomédicaments, Courtaboeuf Cedex, Merck Sharp & Dohme, Kenilworth, New Jersey Novo Nordis Health Care AG, Surich, Switzerland, Pierre Fabre Pharma, Alsch Switzerland, Pierre Fabre Pharma, Alsch Switzerland, Starstedt AG & Co., Sevelen, Switzerland Germany, Natiserland, Pierre Fabre Pharma, Alsch Switzerland, Starstedt AG & Co., Sevelen, Switzerland Managones, Switzerland, Uffor (International) Ltd, Reinach, Switzerland, Takeda, Glattpark, Switzerland, Gallen, Switzerland, Takeda, Glattpark, Switzerland, Al Singapore. 6 Payment for expert testimony XNone 7 Support for attending None	Nono		
Iectures, presentations, speakers bureaus, manuscript writing or educational events Iecturing from: Danube University of Krems, Austria, European of Anesthesiology and Intensive Care, Brussels, Korean Society of Patient Blood Management, Korea, Korean Society of Anesthesiologists, See Network for the Advancement of Patient Blood Management, Haemostasis and Thrombosis, Pa France, Alexion Pharmaceuticals Inc., Boston, N. AstraZeneca AG, Baar, Switzerland, Baraun Melsungen AG, Z Switzerland, B. Braun Melsungen AG, Melsunge Germany, CSL Behring GmbH, Hattersheim am Germany and Berne, Switzerland, Celgene Intel II Sårl, Couvet, Switzerland, Daikhi Sankyo AG, Switzerland, Haemonetics, Braintree, MA, USA, Instrumentation Laboratory (Werfen), Bedford USA, LFB Biomédicaments, Courtaboeut Cedex, Merck Sharp & Dohme, Kenilworth, New Jersey Novo Nordisk Health Care AG, Zurich, Switzerland, Pierre Fabre Pharma, Alsch Switzerland, Pierre Fabre Pharma, Alsch Switzerland, Pierre Fabre Pharma, Misch Switzerland, Takeda, Glathark, Switzerland, Takeda, Glathark, Switzerland, Takeda, Glathark, Switzerland, Teine, Switzerland, Teine, Sangapore. 6 Payment for expert testimony X_None 7 Support for attending _X_None			
Iectures, presentations, speakers bureaus, manuscript writing or educational events Iecturing from: Danube University of Krems, Austria, European of Anesthesiology and Intensive Care, Brussels, Korean Society of Patient Blood Management, Korea, Korean Society of Anesthesiologists, See Network for the Advancement of Patient Blood Management, Haemostasis and Thrombosis, Pa France, Alexion Pharmaceuticals Inc., Boston, N. AstraZeneca AG, Baar, Switzerland, Baraun Melsungen AG, Z Switzerland, B. Braun Melsungen AG, Melsunge Germany, CSL Behring GmbH, Hattersheim am Germany and Berne, Switzerland, Celgene Intel II Sårl, Couvet, Switzerland, Daikhi Sankyo AG, Switzerland, Haemonetics, Braintree, MA, USA, Instrumentation Laboratory (Werfen), Bedford USA, LFB Biomédicaments, Courtaboeut Cedex, Merck Sharp & Dohme, Kenilworth, New Jersey Novo Nordisk Health Care AG, Zurich, Switzerland, Pierre Fabre Pharma, Alsch Switzerland, Pierre Fabre Pharma, Alsch Switzerland, Pierre Fabre Pharma, Misch Switzerland, Takeda, Glathark, Switzerland, Takeda, Glathark, Switzerland, Takeda, Glathark, Switzerland, Teine, Switzerland, Teine, Sangapore. 6 Payment for expert testimony X_None 7 Support for attending _X_None			
6 Payment for expert testimony 7 Support for attending 7 Support for attending	lecturing Danube U of Anesth Korean So Korea, Ko Network Managerr France, A AstraZene Switzerlan Germany, Germany	m: versity of Krems, Austria, European So ology and Intensive Care, Brussels, BE ty for Patient Blood Management, Se in Society of Anesthesiologists, Seoul, the Advancement of Patient Blood t, Haemostasis and Thrombosis, Paris on Pharmaceuticals Inc., Boston, MA, AG, Baar, Switzerland, Bayer AG, Züri B. Braun Melsungen AG, Melsungen, L Behring GmbH, Hattersheim am Ma d Berne, Switzerland, Celgene Interna	ciety , oul, Korea, ch, in, tional
testimony	Switzerlan Instrumen USA, LFB Merck Sh Novo Nor PAION De Pharmacc Zürich, Sw Switzerlan Roche Dia Switzerlan Nümbreck Switzerlan Internatic Munich, C sur-Glâne Gallen, Sw	Haemonetics, Braintree, MA, USA, tion Laboratory (Werfen), Bedford, M médicaments, Courtaboeuf Cedex, Fra & Dohme, Kenilworth, New Jersey, U k Health Care AG, Zurich, Switzerland, schland GmbH, Aachen, Germany, nos A/S, Holbaek, Denmark, Pfizer AG, erland, Pierre Fabre Pharma, Alschwil Portola Schweiz GmbH, Aarau, Switze ostics International Ltd, Reinach, Sarstedt AG & Co., Sevelen, Switzerla Germany, Shire Switzerland GmbH, Zu Takeda, Glattpark, Switzerland, Tem I GmbH, Munich, Germany, Vifor Phar many, Neuilly sur Seine, France and V witzerland, Vifor (International) AG, St	A, ance, SA, rland, nd and Ig, ma, illars-
	_None		
	_None		
Detents glassed investigation V. Nage	Name		
8 Patents planned, issued orXNone	_None		
pending			

9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid		DRS is co-chair of the ABC-Trauma Faculty, sponsored by unrestricted educational grants from Novo Nordisk Health Care AG, Zurich, Switzerland, CSL Behring GmbH, Marburg, Germany, LFB Biomédicaments, Courtaboeuf Cedex, France and Octapharma AG, Lachen, Switzerland.
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone	
13	Other financial or non- financial interests	XNone	

DRS academic department is receiving grant support from the Swiss National Science Foundation, Berne, Switzerland, the Swiss Society of Anesthesiology and Perioperative Medicine (SSAPM), Berne, Switzerland, the Swiss Foundation for Anesthesia Research, Zurich, Switzerland, Vifor SA, Villars-sur-Glâne, Switzerland and Vifor (International) AG, St. Gallen, Switzerland.

DRS is co-chair of the ABC-Trauma Faculty, sponsored by unrestricted educational grants from Novo Nordisk Health Care AG, Zurich, Switzerland, CSL Behring GmbH, Marburg, Germany, LFB Biomédicaments, Courtaboeuf Cedex, France and Octapharma AG, Lachen, Switzerland.

DRS received honoraria / travel support for consulting or lecturing from:

Danube University of Krems, Austria, European Society of Anesthesiology and Intensive Care, Brussels, BE, Korean Society for Patient Blood Management, Seoul, Korea, Korean Society of Anesthesiologists, Seoul, Korea, Network for the Advancement of Patient Blood Management, Haemostasis and Thrombosis, Paris, France, Alexion Pharmaceuticals Inc., Boston, MA, AstraZeneca AG, Baar, Switzerland, Bayer AG, Zürich, Switzerland, B. Braun Melsungen AG, Melsungen, Germany, CSL Behring GmbH, Hattersheim am Main, Germany and Berne, Switzerland, Celgene International II Sàrl, Couvet, Switzerland, Daiichi Sankyo AG, Thalwil, Switzerland, Haemonetics, Braintree, MA, USA, Instrumentation Laboratory (Werfen), Bedford, MA, USA, LFB Biomédicaments, Courtaboeuf Cedex, France, Merck Sharp & Dohme, Kenilworth, New Jersey, USA, Novo Nordisk Health Care AG, Zurich, Switzerland, PAION Deutschland GmbH, Aachen, Germany, Pharmacosmos A/S, Holbaek, Denmark, Pfizer AG, Zürich, Switzerland, Pierre Fabre Pharma, Alschwil, Switzerland, Portola Schweiz GmbH, Aarau, Switzerland, Roche Diagnostics International Ltd, Reinach, Switzerland, Sarstedt AG & Co., Sevelen, Switzerland and Nümbrecht, Germany, Shire Switzerland GmbH, Zug, Switzerland, Takeda, Glattpark, Switzerland, Tem International GmbH, Munich, Germany, Vifor Pharma, Munich, Germany, Neuilly sur Seine, France and Villars-sur-Glâne, Switzerland, Vifor (International) AG, St. Gallen, Switzerland, Zuellig Pharma Holdings, Singapore, Singapore.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: September 12, 2022_

Your Name:_Markus J. Wilhelm_

Manuscript Title: Predictors Associated with Mortality of Veno-Venous Extracorporeal Membrane Oxygenation Therapy Manuscript number (if known):_____

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
		needed)	
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony	Berlin Heart GmbH, Berlin, Germany None	Speaker's honoraria
7	Support for attending meetings and/or travel	Berlin Heart GmbH, Berlin, Germany	Reimbursement for travel expenses
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

Berlin Heart GmbH, Berlin, Germany

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.